ESHOPWORLD
13.4.2021 08:03:35 CEST | Business Wire | Press release
eShopWorld (ESW), the leading cross-border ecommerce technology and services provider, today announces the appointment of Martim Avillez Oliveira as Chief Commercial Officer, EMEA and APAC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005546/en/
Oliveira is a former Executive Vice President at global supply chain and logistics specialist, Li & Fung, has 15 years of industry experience in retail and global sourcing, having worked with the world’s leading fashion brands and retailers, including Inditex, Marks & Spencer, J.Crew and Galeria Karstadt Kaufhof, managing end-to-end supply chains.
In his new role, Oliveira will drive forward ESW’s strategic growth and development with a focus on crafting routes to market within and between the EMEA and APAC that enable retailers and brands to meet the huge latent demand for direct-to-consumer (D2C) engagement in these territories. Oliveira previously served as a member of ESW’s Retail Advisory Council, providing strategic guidance and amplifying the company’s cross-border ecommerce proposition globally.
“2020 saw historic growth in year-on-year cross-border ecommerce sales and reinforced the importance of international ecommerce for the retail industry as an enabler to meet customer demand at its point of origin while mitigating against fluctuations in local markets,” said Tommy Kelly, CEO of ESW.
“ESW saw significant growth in demand from consumers in Asian countries, with the Philippines in particular being one of the fastest growing global markets last year for brands and retailers using our technology and services to sell internationally. Martim’s insights, expertise and relationships across both APAC and the EMEA will allow us to expand our reach in these territories, whose emerging middle class will be a significant driver of global demand for Western brands within a short period of time. As a member of the ESW Advisory Council, Martim has already had a significant role in realising our global expansion strategy in these markets and we are very excited to formally welcome him as part of our global leadership team during this time of unprecedented opportunity.”
During his time at Li & Fung, Oliveira, who lived in Hong Kong for 10 years, held full P&L responsibility for business units to excess of $800 million cost of goods and achieved a strong track record of generating year-on-year growth and revenue. He also coordinated the group business development activities in Europe and the US.
“The events of last year have clearly shown retail brands need to mitigate risks, diversify and balance their distribution to thrive. As home to eight of the world's ten largest megacities, Asia, which has a growing digitally native middle class in all countries who are brand and status hungry, offers enormous expansion opportunities for both established heritage and emerging disruptor brands,” commented Oliveira.
“But many of these brands don’t have the digital capabilities, local expertise or capital required to fully leverage international opportunities and, while it may be tempting to look toward marketplaces as a route to these markets, we know the highest value cross-border shoppers want to engage with and buy directly from brands. ESW offers a seamless end-to-end solution that helps brands capitalise on this golden era for direct-to-consumer, cross-border ecommerce.”
Oliveira concluded: “Having been at the forefront of design, product development, global sourcing and production management, ESW represents the next mile in the journey. It’s the upstream part of the chain, moving from physical to digital, focusing on getting goods to international markets, looking at the most cost-effective route and solutions, while delivering fully localised shopping experiences to consumers around the world.”
In addition to his role at ESW, Oliveira is also non-executive and an advisor to Tiger Chark, a New York based strategic Advisory firm, and a member of the board of the Portuguese - Hong Kong Chamber of Commerce and Industry.
Ends
Notes to Editors
About eShopWorld:
ESW is the cross-border ecommerce leader, empowering the world’s best-loved brands and retailers to make global shopping better, safer, simpler and faster, end-to-end. From compliance, data security, fraud protection, taxes, and tariffs to checkout, delivery, returns, customer service, and demand generation, our powerful combination of technology and human ingenuity covers the entire shopper journey across 200 markets.
Methodology:
ESW’s latest consumer survey was fielded from more than 22,000 consumers in 11 countries (Australia, Canada, Chile, France, Germany, Mexico, Russia, Singapore, Turkey, the UK and the US), who were surveyed online in December 2020. Gen Zers are defined as consumers ages 18–24, Millennials as ages 25–40, Gen Xers as ages 41–56, Baby Boomers as ages 57–75 and the Silent generation as ages 76–92. To gauge how Baby Boomers’ global online shopping preferences differ from those of Gen Zers and millennials (shoppers ages 40 and under), ESW looked specifically at survey responses from shoppers in seven countries: Australia, Canada, France, Germany, Russia, the UK and the US.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
